SS
SRPT icon

SBI Securities’s Sarepta Therapeutics SRPT Stock Holding History

SBI Securities’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8K Sell
602
-10
-2% -$189 ﹤0.01% 1790
2026
Q1 		$13.3K Buy
612
+243
+66% +$4.7K ﹤0.01% 1611
2025
Q4 		$7.94K Sell
369
-235
-39% -$4.95K ﹤0.01% 1817
2025
Q3 		$11.6K Buy
604
+541
+859% +$9.64K ﹤0.01% 1702
2025
Q2 		$1.08K Buy
63
+3
+5% +$128 ﹤0.01% 2646
2025
Q1 		$3.83K Sell
60
-67
-53% -$7.05K ﹤0.01% 2006
2024
Q4 		$15.4K Buy
+127
New +$15.6K ﹤0.01% 1459

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

SBI Securities's SRPT Position: Q2 2026 in Review

SBI Securities reduced its Sarepta Therapeutics (SRPT) stake by 1.6% in Q2 2026, selling an estimated $189 and leaving 602 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1790.

SBI Securities first reported a position in SRPT in Q4 2024 and has held it in 7 quarters since. The position peaked at $15.4K in Q4 2024. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • SBI Securities held 602 shares of Sarepta Therapeutics worth $10.8K as of Q2 2026.
  • SBI Securities sold 10 Sarepta Therapeutics shares in Q2 2026, an estimated $189.
  • Sarepta Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1790 holding.
  • SBI Securities first reported a position in Sarepta Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Sarepta Therapeutics position peaked at $15.4K in Q4 2024.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.